New Potential Personalized Medicine Platform

p-medicine project, launched in February this year, is a 4-year Integrated project aiming at developing a new and state-of-the-art IT platform for personalized medicine. The researchers elaborated the first deliverables according to the agreed 'Description of Work', they identified and described motivated use case scenarios by underlining the p-medicine platform's end user needs and requirements.

"It is the purpose of p-medicine to deliver an architecture that will allow to drive medicine to more individualized treatments based on exploiting the vast amount of heterogeneous data of single patients by software, services, tools and models that will support physicians in decision making in their daily care of patients," said p-medicine project coordinator Prof. Dr. Norbert Graf, Director of the Department of Pediatric Oncology and Hematology, Saarland University (Germany).

"All presented use-case scenarios have been actively discussed and only the mutually agreed versions have been considered," added Prof. Graf, who helped elaborate the first project deliverables while contributing and coordinating the input from all project partners.

"Project partners demonstrated a strong commitment and an active enrolment. The p-medicine project is an interdisciplinary and collaborative research activity. One of the learnt lessons is: we are in the right direction with high skilled and experienced partners," concluded Prof. Graf.

In p-medicine 19 partners from 9 European countries and Japan have dedicated themselves to enable support and sustain new knowledge and innovative technologies to overcome current problems in clinical research and pave the way for a more individualized treatment of cancer. p-medicine unifies European experts in different fields (clinicians, biologists, IT-specialists, ethical and legal experts) to develop and exploit data and tools that support translational research in every aspect.

For further information, please visit:
http://www.p-medicine.eu

About p-medicine project
The European Integrated Project p-medicine is supported by the European Commission under the 7th Framework Programme, Grant agreement number 270089.

Most Popular Now

Amgen and Allergan's MVASI™ (bevacizumab-awwb) and…

Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTITM (trastuzumab-anns), a bio...

Compound found in red wine opens door for new trea…

Like to unwind with a glass of red wine after a stressful day? Don't give alcohol all the credit. New research has revealed that the plant compound resveratrol, which is ...

HIV vaccine nears clinical trial following new fin…

A promising vaccine that clears an HIV-like virus from monkeys is closer to human testing after a new, weakened version of the vaccine has been shown to provide similar p...

Mylan and Upjohn, a division of Pfizer, to combine…

HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) today announced a definitive agreement to combine Mylan with Upjohn, Pfizer's o...

Leading oncologists and nutritionists pinpoint are…

An international collaborative led by Ludwig Cancer Research and Cancer Research UK has identified key areas that are central to uncovering the complex relationship betwe...

Closing the door: breaking new ground related to a…

In order to sustain fast growth, cancer cells need to take up nutrients at a faster rate than healthy cells. The human glutamine transporter ASCT2 allows the amino acid g...

FDA approves first generics of Lyrica

On July 19, the U.S. Food and Drug Administration approved multiple applications for first generics of Lyrica (pregabalin) for the management of neuropathic pain associat...

Roche and Spark Therapeutics, Inc. announce extens…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ("Spark") announced that Roche has extended the offering period of its previously announced...

FDA approves first treatment for severe hypoglycem…

The U.S. Food and Drug Administration today approved Baqsimi nasal powder, the first glucagon therapy approved for the emergency treatment of severe hypoglycemia that c...

Rye is healthy, thanks to an interplay of microbes

Eating rye comes with a variety of health benefits. A new study from the University of Eastern Finland now shows that both lactic acid bacteria and gut bacteria contribut...

GSK completes transaction with Pfizer to form new …

The Joint Venture brings together two highly complementary portfolios of trusted consumer health brands, including GSK's Sensodyne, Voltaren and Panadol and Pfizer's Advi...

Eating more plant-based foods may be linked to bet…

Eating mostly plant-based foods and fewer animal-based foods may be linked to better heart health and a lower risk of dying from a heart attack, stroke or other cardiovas...